The Healthy Aging Company

DEVELOPING GAME CHANGER THERAPIES FOR
Neurodegenerative diseases with potential for other age-related diseases

THAC primarily focuses on age-related diseases,
such as:

Type 2 Diabetes Mellitus,
Neuropathy, and
Alzheimer’s diseases

The Problem

Age related diseases are a global epidemic as the society grows older

Metabolic dysfunction is a key factor in most aged-related diseases

90%

of older adults have at least one chronic condition, nearly 80% have at least 2

Global epidemic

Cardiovascular, obesity, diabetes and Alzheimer’s are global epidemic diseases

80%

Age related diseases represent 80% of the US Medicare budget

$30 trillion

Over $30 trillion over the next 20 years

THAC drug candidates are intended to delay disease progression, delay premature death, prevent T2DM complications (i.e., peripheral neuropathy, e.g., diabetic foot wounds and amputations), and improve patient quality of life.

THAC develops GMP approved, first-in-class,
first-in-man molecules

THAC develops biological and recombinant drug candidates with the active ingredient ALF-5755 (recombinant human protein derived from C-type lectin Reg3α), a GMP approved, first-in-class, first-in-man molecule.
 
THAC innovative drug candidates have unique biological properties, a combination of anti-oxidative ROS-scavenger and anti-inflammatory activity to tackle insulin resistance, the root cause of Type 2 diabetes mellitus, and muscle glucose uptake, decrease fat lean without overall weight loss and restore gut microbiota composition.

THAC is a resident at The Institute of Diabetes,
Paris (France)
and at the University of South Florida (US)

The Founders

THAC is a mature biopharmaceutical company. THAC was created by Prof. Christian Bréchot MD & PhD, Dr Gilles Amouyal MD & PhD, Dr Paul Amouyal MD, Prof. Christophe Magnan PhD,

Christian Bréchot
MD & PhD

CEO/ Co-Founder

Gilles Amouyal
MD & PhD

Co-Founder

Paul Amouyal
MD

Co-Founder

Christophe Magnan
PhD

Head of Research/ Co-Founder

Scientific Consultants

Dr. Aurélie Joly-Amado, PHD

Research Scientist University of South Florida USA

Consultant on neurodegenerative diseases

Dr. Céline Cruciani-Guglielmacci, PhD

Professor University Paris Cité – Paris France

Consultant on Metabolic syndrome and diabetes

Explore Our Blog

Contact us

♦ Our location in France
Cochin Hospital – APHP
Incubateur Paris Biotech Santé
24 Boulevard du Faubourg Saint Jacques
75014 Paris, France
 
♦ Our location in the United States
University of South Florida
USF Connect Incubator
3702 Spectrum Blvd.
Tampa, FL 33612, USA